scholarly journals Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

2019 ◽  
Vol 25 (11) ◽  
pp. 2113-2123 ◽  
Author(s):  
Zachariah DeFilipp ◽  
Anjali S. Advani ◽  
Veronika Bachanova ◽  
Ryan D. Cassaday ◽  
Daniel J. Deangelo ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Cellular Therapy ◽  
Lymphoblastic Leukemia ◽  
Hematopoietic Cell ◽  
Evidence Based ◽  
Adult Acute Lymphoblastic Leukemia ◽  
American Society

scholarly journals When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?

Hematology ◽  
2012 ◽  
Vol 2012 (1) ◽  
pp. 382-388 ◽  
Author(s):  
Hillard M. Lazarus ◽  
Anjali S. Advani
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Philadelphia Chromosome ◽  
Hematopoietic Cell ◽  
Related Factors ◽  
Molecular Features ◽  
Adult Acute Lymphoblastic Leukemia

Abstract Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease affected by many patient- and disease-related factors, including age, immunologic subtype, and clinical, genetic, and molecular features. Allogeneic hematopoietic cell transplantation (HCT) has occupied an increasing therapeutic role as a result of significant improvements in supportive care and histocompatibility testing. ALL Philadelphia chromosome–negative patients formerly excluded now are considered HCT candidates and survival rates with alternative donors may approach those obtained with matched-related donors. Reduced-intensity conditioning rather than myeloablative conditioning appears to provide comparable patient outcome results although these observations have not been validated in prospective studies. Improved tools can identify patients thought to be in remission based on morphology but who have active disease at the molecular or immunophenotypic level (minimal residual disease). Using B-cell antigen panels, clone-specific immunoglobulins, or T-cell receptor rearrangements to detect positivity at thresholds of at least 1 in 104 cells, such patients may be taken to HCT. The ongoing advances in conventional therapy intensity, however, now yield improved results and ongoing reassessment of the place of HCT needs to be continued; every effort should be made to enroll eligible patients in clinical trials.

Sign in / Sign up

Export Citation Format

Share Document